Elefteri M Buset
Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
Samaras P, Renner C, Stahel R, Knuth A, Taverna C, Schäfer N, Mischo A, Schanz U, Siciliano R, Honegger H, Haile S, Buset E, Petrausch U, Zardavas D, Stenner-Liewen F. Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. Swiss Med Wkly 2013; 143:w13791.
May 7, 2013Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
May 7, 2013Swiss Med Wkly 2013; 143:w13791
Samaras Panagiotis, Renner Christoph, Stahel Rolf, Knuth Alexander, Taverna Christian, Schäfer Niklaus G, Mischo Axel, Schanz Urs, Siciliano Raffaele D, Honegger Hanspeter, Haile Sarah, Buset Elefteri M, Petrausch Ulf, Zardavas Dimitrios, Stenner-Liewen Frank
Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation
Samaras P, Renner C, Knuth A, Stahel R, Stussi G, Schanz U, Pestalozzi B, Honegger H, Mischo A, Petrausch U, Haile S, Siciliano R, Buset E, Stenner-Liewen F. Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. Oncology 2010; 79:93-97.
Nov 15, 2010Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation
Nov 15, 2010Oncology 2010; 79:93-97
Samaras Panagiotis, Renner Christoph, Knuth Alexander, Stahel Rolf A, Stussi Georg, Schanz Urs, Pestalozzi Bernhard C, Honegger Hanspeter, Mischo Axel, Petrausch Ulf, Haile Sarah, Siciliano Raffaele Daniele, Buset Elefteri M, Stenner-Liewen Frank
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
Samaras P, Stenner-Liewen F, Knuth A, Stahel R, Stussi G, Schanz U, Honegger H, Mischo A, Petrausch U, Buset E, Haile S, Siciliano R, Blickenstorfer M, Renner C. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann Hematol 2010; 90:89-94.
Aug 13, 2010Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
Aug 13, 2010Ann Hematol 2010; 90:89-94
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Stahel Rolf A, Stussi Georg, Schanz Urs, Honegger Hanspeter, Mischo Axel, Petrausch Ulf, Buset Elefteri M, Haile Sarah, Siciliano Raffaele Daniele, Blickenstorfer Marcel, Renner Christoph